Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

Add TROV Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 5/14/2019 11:03:58 AM - Followers: 77 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.


Trovagene Closes Acquisition of CLIA Laboratory Assets
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board

Targeted $40 Billion market space:
TROV market space

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Post-effective Amendment to Registration Statement (pos Am) 05/21/2019 09:13:07 AM
TROV News: Small Company Offering and Sale of Securities Without Registration (d) 05/20/2019 05:13:39 PM
TROV News: Post-effective Amendment to Registration Statement (pos Am) 05/17/2019 05:27:03 PM
TROV News: Post-effective Amendment to Registration Statement (pos Am) 05/14/2019 11:56:18 AM
TROV News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/13/2019 04:15:50 PM
News News Alert: Post-effective Amendment to Registration Statement (pos Am) 05/21/2019 09:13:07 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1413   Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Source: Edgar (US abracky 05/14/19 11:03:58 AM
#1412   Current Report Filing (8-k) Source: Edgar (US Regulatory)     UNITED STATES  abracky 05/14/19 11:03:12 AM
#1411   Trovagene Announces Equity Investment of $1.5 Million at abracky 05/14/19 11:01:14 AM
#1410   Additional Proxy Soliciting Materials (definitive) (defa14a) Source: Edgar (US abracky 04/24/19 02:04:57 PM
#1409   Current Report Filing (8-k) Source: Edgar (US Regulatory)     UNITED STATES S abracky 04/24/19 02:04:26 PM
#1408   * * $TROV Video Chart 04-23-2019 * * ClayTrader 04/23/19 06:43:00 PM
#1407   EPIC TROV Lets see $150. level again as Lanceo 04/23/19 12:36:43 PM
#1406   In at $3.60. This could make a run BillG2436 04/23/19 11:55:42 AM
#1405   News: $TROV Trovagene Announces Data Demonstrating Significant Synergy whytestocks 04/23/19 09:50:40 AM
#1404   Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib abracky 04/23/19 08:44:03 AM
#1403   Up on news. BillG2436 04/23/19 08:12:07 AM
#1402   Small Company Offering and Sale of Securities Without abracky 04/17/19 12:02:28 PM
#1401   Agreed, watching anything else? st0ckdiva 04/05/19 01:11:11 PM
#1400   Good point and good info. But I SmallCapStockGuy 04/05/19 01:06:14 PM
#1399   news https://stockactionnow.wordpress.com/2019/04/05/4-healthcare-stocks- st0ckdiva 04/05/19 01:05:06 PM
#1398   News: $TROV Trovagene Announces Update to Phase 1b/2 whytestocks 04/05/19 10:01:11 AM
#1397   News: $TROV Trovagene Announces $1.5 Million Equity Investment whytestocks 04/05/19 09:51:32 AM
#1396   Price doubles today! iamsureofit 04/05/19 09:24:54 AM
#1395   Shorts Lose shirts&Cry Mama When News hits $200 Lanceo 04/03/19 12:54:40 AM
#1394   Current Report Filing (8-k) Source: Edgar (US Regulatory)     UNITED STATES SE abracky 04/02/19 12:53:12 PM
#1393   News: $TROV Early Data from Phase 2 Trial whytestocks 04/02/19 08:10:41 AM
#1392   TROV Daily Chart: Golden_Cross 04/02/19 04:01:20 AM
#1391   Lock Share High w/ News TROV Blasting back Lanceo 04/02/19 01:20:41 AM
#1390   im in this @4.40 DeliverySuccess 04/01/19 05:13:00 PM
#1389   * * $TROV Video Chart 04-01-2019 * * ClayTrader 04/01/19 05:02:56 PM
#1388   Anyone have the 2018 and 2019 split figures XenaLives 04/01/19 04:42:00 PM
#1387   News: $TROV Phase 1b/2 Dose Escalation Trial of whytestocks 04/01/19 01:10:38 PM
#1386   Volatility halt Awl416 04/01/19 01:10:00 PM
#1385   so, any good news... will Trov jump AnthonyS 04/01/19 07:31:26 AM
#1384   Hello All - Newbie here trying to learn. Chambers3t0 03/20/19 09:31:28 AM
#1383   if the data reported in April is excellent, tilator 03/13/19 07:01:56 AM
#1382   if the data reported in April is excellent, Decimus1 03/12/19 05:52:39 PM
#1381   Stock is being shorted. Shorts are now going to Decimus1 03/12/19 04:50:10 PM
#1380   Added today. Fares 03/12/19 03:41:41 PM
#1379   And pre market ops equals 2,88 - 50% Klinsmann 03/12/19 11:56:53 AM
#1378   *Trovagene Regains Compliance With Nasdaq Listing Requirements Decimus1 03/12/19 11:54:24 AM
#1377   They have had that for a long time. Johnny_C 03/12/19 07:46:43 AM
#1376   they have nearly 11% institutional ownership. Decimus1 03/12/19 02:30:39 AM
#1375   I think tomorrow is the day it skyrockets Decimus1 03/11/19 08:58:30 PM
#1374   It closed sub $5.00. Now about 5 Johnny_C 03/11/19 04:27:40 PM
#1373   looking good folks. Decimus1 03/11/19 11:03:13 AM
#1372   BPTH is strange, 600k shares. How does Johnny_C 03/11/19 08:36:09 AM
#1371   This will run up this week. Lot happening at Decimus1 03/10/19 04:30:03 PM
#1370   Yes.. been in TROV a very long time Johnny_C 03/10/19 02:18:08 PM
#1369   he nailed bpth from 11 to 73 in Rocketstockpix 03/10/19 10:04:30 AM
#1368   They should fall off the non compliant list, Full Contact Yoga 03/10/19 01:51:40 AM
#1367   Why ? Is it because they need to marina22 03/10/19 12:37:56 AM
#1366   There is also possible news on Monday. Dip will Decimus1 03/09/19 07:06:14 PM
#1365   I'd say pay close attention to the premarket, Milo1 03/09/19 06:09:14 PM
#1364   So they plan to sell 600K shares, after Milo1 03/09/19 06:07:21 PM